Edwards Lifesciences Corp (EW) is held by 6 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund adding and 4 funds trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $10.9M sold). Latest close $105.23 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 10, 2026 · Congress to Nov 16, 2026.
Wedgewood Partners · Mirova US · OrbiMed Advisors — 6 tracked funds hold EW. See all holders.
Insiders bought on the open market (0 purchases, $0) vs 11 sales ($10.9M). Insider trading
Syndax Pharmaceuticals Inc (SNDX) · O REILLY AUTOMOTIVE INC (ORLY) · BOSTON SCIENTIFIC CORP (BSX) · NEXTERA ENERGY INC (NEE) · ELI LILLY & Co (LLY) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Wedgewood Partners | 3.08% | 165,208 | TRIMMED (-3.4%) Q3 filed Nov 16 |
| Mirova US | 2.47% | 2,540,381 | TRIMMED (-3.3%) Q3 filed Nov 5 |
| OrbiMed Advisors | 1.40% | 834,900 | TRIMMED (-32.2%) Q3 filed Nov 16 |
| Torray Investment Partners LLC | 0.04% | 2,994 | HELD Q3 filed Oct 30 |
| Deerfield Management | 0.01% | 13,702 | HELD Q3 filed Nov 16 |
| Guinness Asset Management | 0.01% | 5,886 | ADDED (+27.2%) Q3 filed Nov 5 |
| Viking Global Investors | — | — | EXITED |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: +14.6% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 1,334 of 8,857 filers |
| Long-only filers among them | 1,328 |
| Change vs 2026 Q1 | +49 net · 1,132 entered · 1,083 exited |
| Shares reported, all filers | 519,669,388 |
| Reported value, all filers | $46.1B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | NYSE |
| Industry | Orthopedic, Prosthetic & Surgical Appliances & Supplies (SIC 3842) |
| Revenue · FY2025 | $6.1B |
| Net income · FY2025 | $1.1B |
| Total assets · FY2025 | $13.7B |
| Shares outstanding | 576,400,000 |
| Market cap (at latest close) | $60.7B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 31, 2026.
| Shares short · Oct 15, 2026 | 9,333,399 |
| Share of shares outstanding | 1.62% |
| Days to cover | 2.46 |
Shares short at recent settlements — Jul 31, 2026: 10.0M · Aug 14, 2026: 10.2M · Aug 31, 2026: 9.0M · Sep 15, 2026: 9.1M · Sep 30, 2026: 9.5M · Oct 15, 2026: 9.3M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 31, 2026.
| Shares failed to deliver · Oct 14, 2026 | 18 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | <0.1% |
Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 74 · Oct 14, 2026: 18.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 31, 2026.
0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 11 sales by 7 insiders ($10.9M).
Source: SEC Form 4 filings. Open-market transactions only.
Recent open-market trades
| Date | Insider | Role | Buy / Sell | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Nov 10, 2026 | Lippis Daniel J. | CVP, TAVR | Sell | 619 | $104.25 | $64.5K | SEC filing |
| Nov 9, 2026 | Zovighian Bernard J | CEO | Sell | 9,184 | $103.39 | $949.5K | SEC filing |
| Nov 9, 2026 | Zovighian Bernard J | CEO | Sell | 13,916 | $102.78 | $1.4M | SEC filing |
| Nov 9, 2026 | BOBO DONALD E JR | CVP,Strategy/Corp Development | Sell | 48,900 | $103.05 | $5.0M | SEC filing |
| Oct 8, 2026 | Lippis Daniel J. | CVP, TAVR | Sell | 619 | $85.65 | $53.0K | SEC filing |
| Sep 11, 2026 | Lippis Daniel J. | CVP, TAVR | Sell | 619 | $87.51 | $54.2K | SEC filing |
| Aug 31, 2026 | Dahl Andrew M. | SVP, Corporate Controller | Sell | 544 | $91.06 | $49.5K | SEC filing |
| Aug 28, 2026 | Bruls Annette | CVP, EMEACLA | Sell | 2,644 | $89.98 | $237.9K | SEC filing |
| Aug 26, 2026 | Chopra Daveen | CVP, TMTT, Surgical & IHFM | Sell | 1,154 | $91.76 | $105.9K | SEC filing |
| Aug 26, 2026 | Chopra Daveen | CVP, TMTT, Surgical & IHFM | Sell | 30,646 | $90.99 | $2.8M | SEC filing |
Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| Aug 31, 2026 | Dahl Andrew M. | Officer | 544 | $49.5K | Aug 31, 2026 | SEC filing |
| Aug 28, 2026 | Bruls Annette | Officer | 2,644 | $237.9K | Aug 28, 2026 | SEC filing |
| Aug 26, 2026 | Markowitz Wayne | Officer | 1,240 | $113.4K | Aug 26, 2026 | SEC filing |
| Aug 26, 2026 | Chopra Daveen | Officer | 31,800 | $2.9M | Aug 26, 2026 | SEC filing |
| Aug 11, 2026 | Lippis Daniel J. | Officer | 1,857 | $170.9K | Aug 11, 2026 | SEC filing |
| Jul 30, 2026 | Ullem Scott B. | Former Affiliate | 50,000 | $4.6M | Jul 30, 2026 | SEC filing |
| Jul 30, 2026 | Markowitz Wayne | Officer | 147 | $12.6K | Jul 30, 2026 | SEC filing |
| Jul 28, 2026 | Markowitz Wayne | Officer | 9,628 | $819.0K | Jul 28, 2026 | SEC filing |
| Jul 27, 2026 | Zovighian Bernard J | Officer, Director | 2,921 | $245.1K | Jul 27, 2026 | SEC filing |
| May 29, 2026 | Ullem Scott B. | Former Affiliate | 64,152 | $5.6M | May 29, 2026 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| Apr 29, 2026 | Vanguard Capital Management | SC 13G | 43,477,533 | 7.5% | Mar 31, 2026 | SEC filing |
| Mar 26, 2026 | The Vanguard Group | SC 13G/A | 0 | 0.0% | Mar 13, 2026 | SEC filing |
| Oct 17, 2025 | BlackRock, Inc. | SC 13G/A | 44,267,376 | 7.5% | Sep 30, 2025 | SEC filing |
| Aug 12, 2025 | Wellington Management Group LLP | SC 13G/A | 19,826,483 | 3.4% | Jun 30, 2025 | SEC filing |
| Jan 30, 2025 | The Vanguard Group | SC 13G/A | 69,131,602 | 11.7% | Dec 31, 2024 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).
Industry: Orthopedic, Prosthetic & Surgical Appliances & Supplies (SIC 3842). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.
None of the members who traded this stock in the current window sit on these committees.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Lobbying: 327 Lobbying Disclosure Act filings named this company as client, 2004–2026; most common issues: Medicare/Medicaid (266), Health Issues (248), Taxation/Internal Revenue Code (134).
Federal contracts: $67.1M in obligated amounts, fiscal years 2021–2026.
| Fiscal year | Obligated amount |
|---|---|
| FY2021 | $17.5M |
| FY2022 | $20.6M |
| FY2023 | $23.2M |
| FY2024 | $5.8M |
| FY2025 | $0 |
| FY2026 | $0 |
Largest awards collected
| Award ID | Agency | Amount | Start |
|---|---|---|---|
| 36C24922P0612 | Department of Veterans Affairs | $454.4K | May 27, 2022 |
| 36C25821P0209 | Department of Veterans Affairs | $445.1K | Jun 8, 2021 |
| 0011 | Department of Defense | $390.0K | Oct 1, 2016 |
| 36C24821P0717 | Department of Veterans Affairs | $384.8K | Feb 22, 2021 |
| 36C25622P1517 | Department of Veterans Affairs | $358.5K | Sep 30, 2022 |
Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.
Financial Screens
· Buffett — Companies with high ROE sustained for more than a decade
· Graham — Sound finances and a long run of profits
Chart Signals
· Monthly Uptrend — Price above its 12-month moving average
· 52-Week High — Recently printed a new 52-week high
· Top Relative Strength — Top 20% of the universe by 6-month return
Key figures
· Buffett — Latest ROE: 10.4% · Years ROE ≥15% (of 10): 9 · 10-yr avg ROE: 23.3% · Latest net income: $1.1B
· Graham — Current ratio: 3.72 · Straight profitable years: 18 · Debt ratio: 0.33 · Latest net income: $1.1B
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
· Politician BEST — appeared in 2 of the last 20 quarterly lists; latest 2023 Q2, ranked #46 of 50.
| 13F signal (2021 Q3 – 2026 Q1) | Events | Win rate | Avg return | SPY | Excess |
|---|---|---|---|---|---|
| Heavy accumulation — 3+ tracked funds increased together | 2 | 0.0% | -8.4% | +1.9% | -10.2% |
Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.
Also held by the tracked funds that hold EW — ranked by lift, the co-holding pattern described in Methodology: Syndax Pharmaceuticals Inc (SNDX) · O REILLY AUTOMOTIVE INC (ORLY) · BOSTON SCIENTIFIC CORP (BSX) · NEXTERA ENERGY INC (NEE) · ELI LILLY & Co (LLY) · THERMO FISHER SCIENTIFIC INC. (TMO).
| Filed | Items | Source |
|---|---|---|
| Nov 4, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
| Aug 28, 2026 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers | SEC filing |
| Jul 23, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
Syndax Pharmaceuticals Inc (SNDX) · Track Record: how the signals scored · Practice timing on EW
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.